| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Coagulation factor concentrates and point-of-care coagulation monitoring: both might be essential for optimal treatment of trauma-induced coagulopathy
|
Grottke, Oliver
|
|
2017
|
4 |
6 |
p. e246-e247
nvt p.
|
artikel
|
| 2 |
Correction to Lancet Haematol 2017; 4: e258–71
|
|
|
2017
|
4 |
6 |
p. e257-
1 p.
|
artikel
|
| 3 |
Correction to Lancet Haematol 2017; 4: e165–75
|
|
|
2017
|
4 |
6 |
p. e257-
1 p.
|
artikel
|
| 4 |
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
|
Davies, Andrew
|
|
2017
|
4 |
6 |
p. e272-e282
nvt p.
|
artikel
|
| 5 |
Evaluation of direct oral anticoagulants in superficial-vein thrombosis
|
Frappé, Paul
|
|
2017
|
4 |
6 |
p. e254-
1 p.
|
artikel
|
| 6 |
Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply
|
Beyer-Westendorf, Jan
|
|
2017
|
4 |
6 |
p. e254-e255
nvt p.
|
artikel
|
| 7 |
Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma
|
Gahrton, Gösta
|
|
2017
|
4 |
6 |
p. e250-e251
nvt p.
|
artikel
|
| 8 |
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan
|
Nieto, Yago
|
|
2017
|
4 |
6 |
p. e283-e292
nvt p.
|
artikel
|
| 9 |
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial
|
Finke, Jürgen
|
|
2017
|
4 |
6 |
p. e293-e301
nvt p.
|
artikel
|
| 10 |
Putting a stop to exsanguination
|
The Lancet Haematology,
|
|
2017
|
4 |
6 |
p. e245-
1 p.
|
artikel
|
| 11 |
Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial
|
Innerhofer, Petra
|
|
2017
|
4 |
6 |
p. e258-e271
nvt p.
|
artikel
|
| 12 |
Subcutaneous rituximab—a meaningful advance in care
|
Assouline, Sarit
|
|
2017
|
4 |
6 |
p. e248-e249
nvt p.
|
artikel
|
| 13 |
Tainted blood: four decades of scandal
|
Mitchell, Fiona
|
|
2017
|
4 |
6 |
p. e256-
1 p.
|
artikel
|
| 14 |
Unrelated donor haemopoietic stem-cell transplantation: ATG or not?
|
Baron, Frédéric
|
|
2017
|
4 |
6 |
p. e252-e253
nvt p.
|
artikel
|
Tijdschrift beschrijving